24 July 2024
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Posting of Circular and Notice of General Meeting
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces further to the announcement made earlier today relating to its proposed Firm Placing, Conditional Placing and Subscription to raise approximately £2.83 million ("Announcement"), that it has despatched the Circular and Notice of General Meeting to Shareholders.
The Directors confirm they are to convene a General Meeting of the Company at 11:00 a.m. on Tuesday 13 August 2024 at Windmill House, Innovation Way, York, YO10 5BR.
The Circular and Notice of General Meeting is available on the Company's website at https://aptamergroup.com/investors/reports-and-presentations/
The results of voting on all resolutions at the General Meeting will be announced via a Regulatory News Service and the full results of the voting will be published on the Company's website, as soon as practicable after the conclusion of the General Meeting.
Capitalised terms used but not otherwise defined in this announcement shall have the meanings ascribed to such terms in the Announcement, unless the context requires otherwise.
- ENDS -
For further information, please contact:
| Aptamer Group plc Dr Arron Tolley
| +44 (0) 1904 217 404 |
| SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Adam Dawes
| +44 (0) 20 3368 3550 |
| Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker
| +44 (0) 20 3657 0050 |
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer® platform.
Optimer® binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion. Optimer® binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer has successfully delivered projects for global pharma companies, diagnostic development companies and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer® technology and processes, scientists and collaborators can make faster, more informed decisions that support discovery and development across the Life Sciences.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.